WuXi Biologics ISIN: KYG970081173 Forum: Aktien User: Summer.76

Wuxi  Bio Dives 4% as Major Shareholder Ditches 1.3% Stake at Over 3.9% Discount http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1239413/company-news/HK6

Big Bank Rating | Goldman Sachs: Quoted from WuXi Biologics (2269 HK) that it will focus on increasing market share in the future and maintain a target price of HK$93 https://finance.sina.cn/hkstock/sckxjfx/2023-01-13/detail-imxzzrzh2340607.d.html?from=wap

Jefferies: Wuxi Bio's Production Capacity Rises Sharply Outside of CN, Ready for More Innovative Collaborations with Clients http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1238183/company-news/HK6

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1238118/company-news/HK6 Macquarie Upgrades WUXI BIO to Outperform, TP Lifted to $80

UBS Upbeat on Recovery Outlook of CN Healthcares in 2023; Top Picks Innovent Bio, Hygeia, Others http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1237870/popular-news/HK6 ... Looking ahead to 2023, UBS remained upbeat on the outlook of China’s healthcare sector, owing to the more predictable industry policies, improving fundamentals of companies and historically-low sector valuation.  ... ... The broker also preferred ...  WUXI BIO (02269 HK) ...

M  Stanley Latest List of Beneficiaries of Reopening (Table) http://www.aastocks.com/en/stocks/news/aafn-con/now.1237774/latest-news u.a. WUXI BIO (02269 HK)

http://www.aastocks.com/en/stocks/news/aafn-con/NOW.1236854/company-news/HK6 CLSA Stays Upbeat on CN Healthcare; Top Picks CSPC PHARMA, SINOPHARM, WUXI BIO etc.

Good News?

🎈

Mit einer Einschätzung zur WuXi im unteren Drittel: https://amp-news.cnyes.com/news/id/5053724

WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers https://www.prnewswire.com/news-releases/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi---multi-specific-t-cell-engagers-301713506.html • WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms • WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales

JPM's Long Position In Wuxi Biologics Rises To 7.03% - HKEx Filing https://kalkinemedia.com/cn/business-news/pharma/brief-jpms-long-position-in-wuxi-biologics-rises-to-703-hkex-filing

"Reputable Report" Citigroup: The current level is a good time to buy the healthcare sub-sector, WuXi Biologics (02269 HK), Zhongsheng Pharmaceutical (01177 HK), Sinopharm (01099 HK), etc. http://www.aastocks.com/tc/stocks/news/aafn-news/NOW.1236181/2

https://amp-news.cnyes.com/news/id/5051081

https://www.wuxibiologics.com/wuxi-biologics-received-first-gmp-certificate-of-ireland-site-from-ireland-health-products-regulatory-authority/

https://www.quamnet.com/post/dvWutYOWLMlBji43kxTcU KGI: WuXi Biologics (02269) Target Price 68 Yuan Stop Loss Price 47 Yuan